Evidence map›Paper›PMID 42793318›Full record

ArticleCurrent issues in molecular biology2026

The Role of 5-HT1A and 5-HT7 Receptors in Anxiety-like Behavior in Mice Treated with Subchronic Atorvastatin.

Judith Espinosa-Raya, Alejandro Trejo-Lazaro, Alfredo Briones-Aranda, Rodrigo Romero-Nava, Fengyang Huang, Refugio Cruz-Trujillo, Josué Vidal Espinosa-Juárez

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Judith Espinosa-RayaLaboratorio Multidisciplinario en Ciencias Biomédicas, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de Mexico 11340, Mexico.ORCID 0000-0002-3181-2920
Alejandro Trejo-LazaroPharmacology Laboratory, Faculty of Human Medicine, Autonomous University of Chiapas, Tuxtla Gutiérrez 29000, Mexico.
Alfredo Briones-ArandaPharmacology Laboratory, Faculty of Human Medicine, Autonomous University of Chiapas, Tuxtla Gutiérrez 29000, Mexico.ORCID 0000-0002-0628-2446
Rodrigo Romero-NavaLaboratorio de Investigación en Genética de Enfermedades Metabólicas, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de Mexico 11340, Mexico.ORCID 0000-0002-8429-5736
Fengyang HuangObesity and Asthma Research Laboratory, Children's Hospital of Mexico Federico Gomez, Mexico City 06720, Mexico.
Refugio Cruz-TrujilloQuímico Farmacobiólogo Program, Research Group on Health and Specialized Metabolites with Pharmacological Potential, Universidad Pablo Guardado Chávez (UPGCH), Libramiento Norte Oriente No. 3450, Tuxtla Gutiérrez 29040, Mexico.ORCID 0000-0003-0151-0435
Josué Vidal Espinosa-JuárezQuímico Farmacobiólogo Program, Research Group on Health and Specialized Metabolites with Pharmacological Potential, Universidad Pablo Guardado Chávez (UPGCH), Libramiento Norte Oriente No. 3450, Tuxtla Gutiérrez 29040, Mexico.ORCID 0000-0002-8123-6343

Funding

Hospital Infantil de México Federico Gómez
6 · The paper itself

Abstract

The polypharmacology of statins includes indirect interactions with the serotonergic system, particularly with the 5-HT1A and 5-HT7 receptors. Statins influence both the expression and function of these receptors, which may affect the regulation of anxiety. The main objective of this study was to examine the effects of subchronic treatment with atorvastatin (STA) and acute treatment with serotonergic drugs on anxiety-like behavior, as well as their possible relationship to changes in the expression of 5-HT1AR and 5-HT7R in different brain regions of mice. In the first phase, the effect of STA (10, 20, or 30 mg/kg daily for 21 days) on anxiety-related exploratory behavior was assessed in male CD1 mice using the avoidance exploratory behavior test. Concurrently, receptor expression levels were measured in the prefrontal cortex, hippocampus, and striatum following STA administration. In the second phase, the effect of serotonergic drugs (0.5 or 1 mg/kg of 8-OH-DPAT, a 5-HT1A/5-HT7 receptor agonist, or WAY100635, a 5-HT1A receptor antagonist) on anxiety-related behaviors was studied in separate groups of animals, stratified by dose, that had previously been treated with or without STA. The persistence of the anxiogenic effect following serotonergic drug administration in mice previously treated with STA may be related to the increased mRNA expression of 5-HT1AR and 5-HT7R observed in the hippocampus, striatum, and prefrontal cortex, although confirmation at the protein level is needed in future studies.

Indexed as

5-HT1A receptor5-HT7 receptor8-OH-DPATanxiety-like behaviorpolypharmacologyWAY100635

Identifiers

PMID42793318
PMCPMC13605594

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.